Try our Advanced Search for more refined results

Exclusivity Parking Still Possible Under Teva Ruling

By Sara Stefanini (April 4, 2008, 12:00 AM EDT) -- The U.S. Food and Drug Administration's finding this year that Teva Parenteral Medicines Inc. would not have to renounce its exclusivity window for its generic granisetron cast light on certain holes in the Medicare Modernization Act of 2003 that could allow generic-drug makers to continue "parking" their exclusivity past the forfeiture deadline the legislation attempted to set....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections

Law Firms

Companies

Government Agencies

Patents

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!